Acta Scientific Gastrointestinal Disorders (ISSN: 2582-1091)

Guest Editorial Volume 3 Issue 8

Remdesivir-Gate for COVID-19

Mina T Kelleni1,2*

1Assistant Professor of Pharmacology, College of Medicine, Minia University, Egypt
2Assistant Professor of Pharmacology, College of Pharmacy, Jouf University, KSA

*Corresponding Author: Mina T Kelleni, Assistant Professor of Pharmacology, College of Medicine, Minia University, Egypt and Assistant Professor of Pharmacology, College of Pharmacy, Jouf University, KSA.

Received: June 27, 2020; Published: July 01, 2020

×

  On the 29th of May, I’ve explained from a pharmacovigilant point of view why remdesivir is least likely to be considered as a safe treatment for COVID-19 patients and I wish to add some other pieces of evidence not mentioned in that rapid response [1].

×

Citation

Citation: Mina T Kelleni. “Remdesivir-Gate for COVID-19”. Acta Scientific Gastrointestinal Disorders 3.8 (2020): 01.



Member In






Notice: A session had already been started - ignoring session_start() in /home/emailacta1/public_html/functions.php on line 3

News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is August 30, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US